NewsTrending topic
ANKTIVA and IL-15 Immunotherapy: What's Approved, What's Still Being Studied
A viral clip highlights ANKTIVA, an IL-15 immunotherapy already FDA-approved for a form of bladder cancer. Here's what it is, what it's approved for, and what's still just being researched.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A clip shared from a Chris Cuomo interview features Dr. Patrick Soon-Shiong. He talks about ANKTIVA. It's an immunotherapy built around interleukin-15, or IL-15. IL-15 is a molecule. It helps turn on natural killer (NK) cells and other immune cells. These cells spot abnormal cells in the body.
What's actually approved
ANKTIVA (nogapendekin alfa inbakicept) is a real, FDA-approved immunotherapy. It's cleared for one specific form of bladder cancer: BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Doctors use it with BCG (Bacillus Calmette-Guérin) therapy, an older bladder cancer immunotherapy. It's for patients whose cancer didn't respond to BCG alone. The post also mentions faster approval for a lung cancer use in Saudi Arabia. Approval outside the US doesn't mean the same approval exists here. Different countries' regulators can reach different calls, based on different evidence and timelines.
What's still being researched
Researchers are still hard at work studying IL-15-based immunotherapy for other cancer types and combos. It's not yet an approved, widely available treatment beyond its one approved use. The original clip is fairly careful about this. It calls ANKTIVA "not a universal cancer cure" and notes more evidence is needed. That's a fair way to describe where the science stands today.
What to do with this information
Do you or someone you know have bladder cancer that hasn't responded to standard BCG treatment? If so, ANKTIVA is a real, already-approved option. It's worth asking a urologic oncologist about. For other cancer types, IL-15 immunotherapy is still just being studied. Check any claims about it against your own care team or a clinical trial listing, not social media.
How this article was prepared
An AI-assisted editorial system helped prepare this page based on public FDA approval information for ANKTIVA and the original social media post. No named medical reviewer has reviewed it unless one is listed.
Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to bladder cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.